Related Experiment Videos
Lrrk2 pathogenic substitutions in Parkinson's disease
Ignacio F Mata1, Jennifer M Kachergus, Julie P Taylor
1Department of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA.
Neurogenetics
|September 21, 2005
Summary
Researchers identified seven pathogenic mutations in the Leucine-rich repeat kinase 2 (LRRK2) gene linked to autosomal dominant parkinsonism. This study advances understanding of genetic factors in Parkinson's disease.
Area of Science:
- Genetics
- Neuroscience
- Molecular Biology
Background:
- Leucine-rich repeat kinase 2 (LRRK2) mutations are linked to autosomal dominant parkinsonism.
- Parkinson's disease often presents with levodopa-responsive symptoms.
- The LRRK2 gene is located on chromosome 12q12.
Purpose of the Study:
- To identify novel mutations in the LRRK2 gene.
- To investigate genomic multiplications or deletions in LRRK2.
- To analyze the segregation of identified mutations with the disease in families.
Main Methods:
- Sequencing of all 51 exons of the LRRK2 gene in 100 affected probands.
- Semiquantitative analysis for LRRK2 genomic multiplication or deletion.
- Assessment of novel sequence variant frequency in control populations.
Main Results:
- Identified 26 coding variants, including 15 nonsynonymous substitutions.
- Discovered three mutations affecting the same codon (R1441C, R1441G, R1441H).
- Confirmed seven pathogenic coding variants that segregate with autosomal dominant parkinsonism and were absent in controls.
Conclusions:
- Seven novel pathogenic LRRK2 mutations were identified in families with autosomal dominant parkinsonism.
- These findings strengthen the role of LRRK2 in the pathogenesis of Parkinson's disease.
- No genomic multiplications or deletions in LRRK2 were detected in the studied cohort.